Market Reports
![]() |
|
EXECUTIVE SUMMARY i. Nonvascular Stents a. Biliary Stents b. Gastrointestinal Stents c. Pulmonary Stents d. Urologic Stents ii. Combined Market Analysis Exhibit ES-1: Biliary Stents, Market Forecast, 2004-2010 Exhibit ES-2: Gastrointestinal Stents, Market Forecast, 2004-2010 Exhibit ES-3: Pulmonary Stents, Market Forecast, 2004-2010 Exhibit ES-4: Urologic Stents, Market Forecast, 2004-2010 Exhibit ES-5: Nonvascular Stenting, Procedure Volumes Forecast, 2004-2010 Exhibit ES-6: Nonvascular Stents, Market Forecast, 2004-2010 1. CURRENT AND EMERGING STENTING TECHNOLOGIES 1.1 Stent Design 1.1.1 Vascular Stents 1.1.2 Nonvascular Stents 1.1.3 Stent Deployment Mechanisms 1.2 Stent Materials 1.2.1 Metal Stents 1.2.1.1 Absorbable Magnesium Alloys 1.2.1.2 Cobalt Alloys 1.2.1.3 Nickel-Titanium Alloys 1.2.1.4 Stainless Steel 1.2.2 Standard Polymeric Stents 1.2.3 Biodegradable Polymeric Stents 1.3 Stent Coatings 1.3.1 Radiopacity Enhancement 1.3.2 Biocompatibility Enhancement 1.3.3 Active Therapeutic Enhancement 1.3.3.1 Drug-Eluting Stents 1.3.3.1.1 Anti-Restenotic Drug-Eluting Stents 1.3.3.1.2 Drug Delivery Techniques 1.3.4 Stent Coverings and Linings Exhibit 1-1: Selected Biomedical, Clinical, and Technical Stent Requirements Exhibit 1-2: Advantages and Disadvantages of Selected Vascular Stent Designs Exhibit 1-3: Advantages and Disadvantages of Metal Stent Materials Exhibit 1-4: Selected Polymeric Stent Materials Exhibit 1-5: Selected Characteristics of Antirestenosis Agents Used in Drug-Eluting Stents Exhibit 1-6: Advantages and Disadvantages of Nonresorbable and Biodegradable Polymeric Drug Carriers for Drug-Eluting Stents 2. NONVASCULAR STENTS MARKET 2.1 Nonvascular Conditions Targeted by Stenting 2.1.1 Biliary Tract Obstruction 2.1.1.1 Clinical Indications 2.1.1.2 Implantation Technique 2.1.1.3 Biliary Stent Types 2.1.1.3.1 Plastic Devices 2.1.1.3.2 Metal Devices 2.1.1.4 Procedure Volumes 2.1.2 Gastrointestinal Tract Obstruction 2.1.2.1 Colorectal Stenting 2.1.2.1.1 Clinical Indications 2.1.2.1.2 Technology 2.1.2.1.3 Implantation Technique 2.1.2.2 Esophageal Stenting 2.1.2.2.1 Technology 2.1.2.2.2 Implantation Technique 2.1.2.3 Procedure Volumes 2.1.3 Pulmonary Tract Obstruction 2.1.3.1 Clinical Indications 2.1.3.2 Types of Pulmonary Stenting Systems 2.1.3.3 Procedure Volumes 2.1.4 Urinary Tract Obstruction 2.1.4.1 Ureteral Obstruction 2.1.4.1.1 Urinary Stone Disease 2.1.4.1.1.1 Treatment 2.1.4.1.2 Ureteral Strictures 2.1.4.1.2.1 Treatment 2.1.4.1.3 Ureteral Stenting 2.1.4.1.3.1 Implantation Technique 2.1.4.1.3.2 Indwelling Time 2.1.4.2 Urethral Obstruction 2.1.4.2.1 Benign Prostatic Hyperplasia 2.1.4.2.1.1 Treatment 2.1.4.2.2 Urethral Strictures 2.1.4.2.2.1 Treatment 2.1.4.2.3 Urethral Stenting 2.1.4.3 Procedure Volumes 2.2 Market Analysis 2.2.1 Biliary Stents 2.2.1.1 Products 2.2.1.2 Market Forecast 2.2.1.2.1 Competitive Analysis 2.2.2 Gastrointestinal Stents 2.2.2.1 Products 2.2.2.2 Market Forecast 2.2.2.2.1 Competitive Analysis 2.2.3 Pulmonary Stents 2.2.3.1 Products 2.2.3.2 Market Forecast 2.2.3.2.1 Competitive Analysis 2.2.4 Urologic Stents 2.2.4.1 Ureteral Stenting Products 2.2.4.2 Urethral Stenting Products 2.2.4.3 Market Forecast 2.2.4.3.1 Competitive Analysis Exhibit 2-1: 2005, Biliary Obstruction, Facts and Figures Exhibit 2-2: Biliary Stenting, Procedure Volumes Forecast, 2004-2010 Exhibit 2-3: 2005, Colorectal Obstruction, Facts and Figures Exhibit 2-4: 2005, Esophageal Obstruction, Facts and Figures Exhibit 2-5: Gastrointestinal Stenting, Procedure Volumes Forecast, 2004-2010 Exhibit 2-6: 2005, Pulmonary Tract Obstruction, Facts and Figures Exhibit 2-7: Pulmonary Stenting, Procedure Volumes Forecast, 2004-2010 Exhibit 2-8: 2005, Upper Urinary Tract Obstructions, Facts and Figures Exhibit 2-9: 2005, Lower Urinary Tract Obstructions, Facts and Figures Exhibit 2-10: Urologic Stenting, Procedure Volumes Forecast, 2004-2010 Exhibit 2-11: Nonvascular Stenting, Procedure Volumes Forecast, 2004-2010 Exhibit 2-12: Nonvascular Stents, Market Forecast, 2004-2010 Exhibit 2-13: 2006, Selected Metal Biliary Stents Exhibit 2-14: Biliary Stents, Market Forecast, 2004-2010 Exhibit 2-15: 2005, Biliary Stents Market, Share by Supplier Exhibit 2-16: 2006, Selected Colorectal Stents Exhibit 2-17: 2006, Selected Metal Esophageal Stents Exhibit 2-18: Gastrointestinal Stents, Market Forecast, 2004-2010 Exhibit 2-19: 2005, Colorectal Stents Market, Share by Supplier Exhibit 2-20: 2005, Esophageal Stents Market, Share by Supplier Exhibit 2-21: 2006, Selected Pulmonary Stents Exhibit 2-22: Pulmonary Stents, Market Forecast, 2004-2010 Exhibit 2-23: 2005, Pulmonary Stents Market, Share by Supplier Exhibit 2-24: 2006, Selected Ureteral Stents Exhibit 2-25: Urologic Stents, Market Forecast, 2004-2010 Exhibit 2-26: 2005, Ureteral Stents Market, Share by Supplier 3. COMPANY PROFILES 3.1 Abbott Laboratories 3.2 ACMI Corporation/Gyrus Group 3.3 American Medical Systems, Inc. 3.4 C.R. Bard, Inc. 3.5 Boston Scientific Corporation 3.6 Bryan Corporation 3.7 Cook Group 3.8 Cordis Corporation/Johnson & Johnson 3.9 eV3, Inc. 3.10 W.L. Gore & Associates, Inc. 3.11 Guidant Corporation/Boston Scientific Corporation 3.12 Hood Laboratories, Inc. 3.13 Medtronic, Inc. *** This is a partial list of companies, for a full listing request it ***
* Single License allows for report sharing within one company location.
Stents are implantable devices designed to serve as endoluminal scaffolds in the recanalization of occluded or structurally compromised vascular and nonvascular circulatory conduits in various organs and tissues of the human body. Nonvascular applications for stenting include biliary stenting, gastrointestinal stenting, pulmonary stenting, and urologic stenting. In 2005, U.S. sales of nonvascular stents totaled approximately $152 million. Over the forecast period covered by this report, this figure is expected to increase at a compound annual rate of 2.8%, reaching approximately $174 million in the year 2010.
This 150-page report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. nonvascular stents market. Topics discussed in this report include current and emerging stenting technologies (e.g., stent design, materials, and coatings), biliary tract obstruction, gastrointestinal tract obstruction, pulmonary tract obstruction, and urinary tract obstruction.
Abbott Laboratories
ACMI Corporation/Gyrus Group
American Medical Systems, Inc
C.R. Bard, Inc.
Boston Scientific Corporation
Bryan Corporation
Cook Group
Cordis Corporation/Johnson & Johnson
eV3, Inc.
W.L. Gore & Associates, Inc.
Guidant Corporation/Boston Scientific Corporation
Hood Laboratories, Inc.
Medtronic, Inc.
+ MORE
** Corporate License allows for report sharing within all company locations.
This report is listed in the following markets:
Drug Delivery, Gynecology, Oncology and Vascular

